1036-OR: ADA Presidents' Select Abstract: Food Insecurity and Level 3 Hypoglycemia in Non-Insulin-Treated Secretagogue Users (iNPHORM, USA)
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1036-or ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von ALEXANDRIA RATZKI-LEEWING und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Food insecurity is a key risk factor for severe hypoglycemia among insulin users. Whether this extends to non-insulin-treated secretagogue users remains unexamined, despite widespread prescribing of these agents, particularly in cost-sensitive contexts. We analyzed data from the iNPHORM study to address this gap.
Methods
Adults (≥18 years) with type 2 diabetes (T2D) on secretagogues (no insulin) were recruited from a US-wide probability-based internet panel. An online screener, baseline, and ≤12 monthly questionnaires captured Level 3 (severe) hypoglycemia frequency and other participant-reported data. A validated item assessed food insecurity at baseline: “Within the past 12 months, did you ever cut the size of your meals or skip meals because there was not enough money for food?” Complete cases with ≥1 follow-up were analyzed. Multivariable negative binomial regression estimated the association between food insecurity and annualized Level 3 hypoglycemia rates, with follow-up time as an offset. A directed acyclic graph identified confounders.
Results
N=339 were analyzed (male: 50.7%; age: 54.8 [SD 13.2] years; T2D duration: 10 [IQR 12] years). Among those exposed to past-year food insecurity (n=64; 19%), the incidence proportion (IP) of Level 3 hypoglycemia was 34.4 (95% CI 23.9-46.6)% and the incidence rate (IR) was 12.3 (95% CI 5.5-27.1) events per person-year (EPPY). Among those not exposed, the IP was 18.9 (95% CI 14.7-24.0)% and the IR was 2.1 (95% CI 1.3-3.3) EPPY. Food insecurity was associated with an adjusted rate ratio of 2.1 (95% CI 1.4-3.1; p<0.001).
Conclusion
In this first-of-its-kind study, past-year food insecurity was linked to a two-fold higher subsequent annual rate of Level 3 hypoglycemia among non-insulin-treated secretagogue users—one of the largest T2D subgroups in the US. A single food insecurity question may serve as a simple medication-safety screen to flag individuals for whom secretagogue use warrants extra caution. Disclosure A. Ratzki-Leewing: Advisory Panel; Current; Sanofi. Consultant; Current; Vertex Pharmaceuticals Incorporated, Dexcom, Inc. Research Support; Current; Sanofi. Other - Paid presentation; Ended; Abbott. Consultant; Current; Sanofi. J. Black: None. A. Kahkoska: Other - Dexcom provides Devices for clinical research in kind or at reduced cost, through my institution; Current; Dexcom, Inc. Y. Lin: Other - Clinical trial site; Current; DEKA, Zucara Therapeutics. Funding Funding for iNPHORM was provided though an investigator-initiated grant from Sanofi Global.
Zitieren
APA
RATZKI-LEEWING, A., BLACK, J., KAHKOSKA, A., & LIN, Y. K. A. (2026). 1036-OR: ADA Presidents' Select Abstract: Food Insecurity and Level 3 Hypoglycemia in Non-Insulin-Treated Secretagogue Users (iNPHORM, USA). Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1036-or
Vancouver
RATZKI-LEEWING A, BLACK J, KAHKOSKA A, LIN YKA. 1036-OR: ADA Presidents' Select Abstract: Food Insecurity and Level 3 Hypoglycemia in Non-Insulin-Treated Secretagogue Users (iNPHORM, USA). Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1036-or
BibTeX
@article{RATZKILEEWING2026,
author = {RATZKI-LEEWING, ALEXANDRIA and BLACK, JASON and KAHKOSKA, ANNA and LIN, YU KUEI (ALEX)},
title = {1036-OR: ADA Presidents' Select Abstract: Food Insecurity and Level 3 Hypoglycemia in Non-Insulin-Treated Secretagogue Users (iNPHORM, USA)},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1036-or}
}
EUVIMED